ALLHAT, or the Soft Science of the Secondary End Point

Annals of Internal Medicine

Volumn 139, Issue 9, 2003, Pages 777-780

  Messerli, Franz H ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LISINOPRIL; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0347600746     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-139-9-200311040-00012     Document Type: Review

References (20)

1. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97. [PMID: 12479763]
2. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, et al. Rationale and design for the Antihyperrensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens. 1996;9:342-60. [PMID: 8722437]
3. McAlister FA. Applying evidence to patient care: from black and white to shades of grey [Editorial]. Ann Intern Med. 2003;138:938-9. [PMID: 12779305]
4. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1. N Engl J Med. 1986;314:290-9. [PMID: 2867470]
5. Messerli FH, Weber MA. Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors [Letter]. JAMA. 2003;289:2067-8; author reply 2069-70. [PMID: 12709457]
6. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet. 2003;361:195-200. [PMID: 12547541]
7. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563-74. [PMID: 12872052]
8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53. [PMID: 10639539]
9. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet. 2002;360:1903-13. [PMID: 12493255]
10. Altman LK. Use of some hypertension drugs questioned. The New York Times. 29 August 2000; A17.
11. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet. 2000;356:1949-54. [PMID: 11130522]
12. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context [Editorial]. Ann Intern Med. 1995;123: 888-9. [PMID: 7486476]
13. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616-28. [PMID: 2225366]
14. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting - enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-92. [PMID: 12584366]
15. Schrier RW. Diuretic treatment of systolic hypertension in the elderly [Editorial]. Hypertension. 2000;35:1031. [PMID: 10818058]
16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo L Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72. [PMID: 12748199]
17. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279:1903-7. [PMID: 9634263]
18. Messerli FH, Beevers DG, Franklin SS, Pickering TG. Beta-blockers in hypertension - the Emperor has no clothes. Am J Hypertens. [In press.]
19. Messerli FH. Diuretic therapy and renal cell carcinoma - another controversy? [Editorial] Eur Heart J. 1999;20:1441-2. [PMID: 10493838]
20. Tenenbaum A, Motro M, Jonas M, Fisman EZ, Grossman E, Boyko V, et al. Is diuretic therapy associated with an increased risk of colon cancer? Am J Med. 2001;110:143-5. [PMID: 11165556]